Drug Profile
Adeno-thymidine-kinase gene therapy - Crucell
Latest Information Update: 26 Jan 2005
Price :
$50
*
At a glance
- Originator Crucell
- Class Antineoplastics; Gene therapies
- Mechanism of Action Thymidine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 25 Jan 2005 Discontinued - Preclinical for Rheumatoid arthritis in Netherlands (unspecified route)
- 25 Jun 1998 Preclinical development for Rheumatoid arthritis in Netherlands (Unknown route)